Weighing Quality of Life Versus Survival for Patients With Advanced Prostate Cancer

Author(s):  
Raj R. Bhanvadia ◽  
Roger K. Khouri ◽  
Caleb Ashbrook ◽  
Solomon L. Woldu ◽  
Vitaly Margulis ◽  
...  

1970 ◽  
Vol 1 (2) ◽  
Author(s):  
Chenglin Huang

Objective: To investigate the feasibility of transurethral resection of prostate and the treatment of advanced prostate cancer and bladder outlet infarction, and to analyze the therapeutic effect. Methods: 34 patients with advanced prostate cancer admitted in our hospital from April 2014 to April 2014 were divided into control group (17 cases) with routine endocrine therapy. The study group (17 cases) underwent urethral resection surgery Combined with endocrine therapy, through the relevant indicators of prostate treatment were observed to explore the two groups of patients with therapeutic effect. Results: According to the related indexes of prostate treatment, the treatment effect of the study group was significantly better than that of the control group, and the data of the two groups were statistically significant (P<0.05). Conclusion: The treatment of advanced prostate cancer patients with endocrine combined with transurethral resection of the prostate can effectively treat the symptoms of bladder outlet infarction and improve the quality of life of patients. It has certain value in clinical treatment.


Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 147
Author(s):  
Alexander Kretschmer ◽  
Roderick C. N. van den Bergh ◽  
Alberto Martini ◽  
Giancarlo Marra ◽  
Massimo Valerio ◽  
...  

With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.


1999 ◽  
Vol 91 (4) ◽  
pp. 381-382
Author(s):  
J.-F. Caubet ◽  
C. M. Moinpour ◽  
A. Troxel ◽  
L. C. Lovato ◽  
M. Eisenberger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document